EUVIMEDEUVIMED entdecken
Crossref

A Novel d -Amino Acid-Composed GRPR-Targeted Peptide in Glioma

Xueyuan Ling, Jiyun Shi iD, Yutong Zhao, Ziyang Li, Liangpeng Chen, Yangyang Liu, Liao Wang, Hongbin Li, Xin Wang, Di Fan, Deling Li iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c00756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Xueyuan Ling und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing 100070, China. Hauptthemen laut MEDLINE: Glioma, Bombesin, Receptors, Bombesin, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrin-releasing peptide receptor (GRPR) is overexpressed in glioma cells and can be specifically bound by Bombesin (BBN). Many molecular imaging agents based on the BBN structure have been tested in clinical trials and have shown promising results, but their in vivo stability needs to be improved. The aim of this study is to develop a novel d-amino acid-composed peptide BBN [as BBN(D)] and test its imaging performance by synthesizing two probes, i.e., BBN(D)-Cy5.5 and [68Ga]Ga-DOTA-BBN(D), respectively, for near-infrared (NIR) fluorescence and PET/CT imaging. The HPLC purity of BBN(D)-Cy5.5 and DOTA-BBN(D) was >95%. And the mass spectrometry was used to confirm the identity of the product, LC-MS (ESI+) 528.5 was found [M+2H]/2. GRPR expression in U87-MG and glioma primary cells was confirmed by immunofluorescence. The in vitro. incubation of cells and BBN(D)-Cy5.5 exhibited a strong fluorescent signal and can be blocked by BBN. The in vivo subcutaneous and intracranial murine xenograft glioma models with two cell lines also demonstrated high specificity and tumor accumulation of BBN(D)-Cy5.5 and [68Ga]Ga-DOTA-BBN(D) imaging tracers. PET/CT imaging with [68Ga]Ga-DOTA-BBN(D) revealed optimal imaging at 40 min postinjection. Fluorescence imaging with BBN(D)-Cy5.5 was optimal at 4 h for subcutaneous models with tumor-to-background ratios peaked at 2.02 ± 0.136 and 2.00 ± 0.129 at 4 h. Biodistribution experiments confirmed that BBN(D) enhanced the accumulation of the probe in tumor tissue and endowed the probe with the ability to cross the blood-brain barrier; at 60 min postinjection of the probe through the teil vein, the uptake of [68Ga]Ga-DOTA-BBN was less than 0.05%ID/g, while the uptake of [68Ga]Ga-DOTA-BBN reached 0.70 ± 0.28%ID/g. The pathology and GRPR staining of ex vivo tissue from murine xenograft glioma models demonstrated strong consistency with fluorescence and PET/CT imaging. In conclusion, this study demonstrated that the d-amino acid-based BBN [BBN(D)] may provide specific imaging for glioma with high stability preoperatively and intraoperatively, warranting further exploration for clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBombesinReceptors, BombesinBrain NeoplasmsAmino AcidsPeptidesAnimalsHumansMiceCell Line, TumorPositron Emission Tomography Computed TomographyGallium RadioisotopesTissue DistributionMice, NudeCarbocyanines

Stichwörter der Autor:innen

Cyanine5.5(Cy5.5)Gallium-68(68Ga)bombesind-amino acid peptidegastrin releasing peptide receptor(GRPR)near-infrared (NIR) fluorescencepositron emission tomography(PET)

Substanzen

BombesinReceptors, BombesinGallium RadioisotopesAmino AcidsPeptidesCarbocyaninesCY5.5 cyanine dye

Autor:innen und Institutionen

  • Department of Neurosurgery, Beijing Tiantan Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing 100070, China.
  • Department of Nuclear Medicine, Beijing Tiantan Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing 100070, China.
  • Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Beijing Neurosurgery Institute, Capital Medical University, Beijing 100070, China.
  • China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing 100070, China.

ORCID-Profile: Jiyun Shi, Deling Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ling, X., Shi, J., Zhao, Y., Li, Z., Chen, L., Liu, Y., Wang, L., Li, H., Wang, X., Fan, D., & Li, D. (2026). A Novel d -Amino Acid-Composed GRPR-Targeted Peptide in Glioma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00756

Vancouver

Ling X, Shi J, Zhao Y, Li Z, Chen L, Liu Y, et al. A Novel d -Amino Acid-Composed GRPR-Targeted Peptide in Glioma. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c00756

BibTeX
@article{Ling2026,
  author = {Ling, Xueyuan and Shi, Jiyun and Zhao, Yutong and Li, Ziyang and Chen, Liangpeng and Liu, Yangyang and Wang, Liao and Li, Hongbin and Wang, Xin and Fan, Di and Li, Deling},
  title = {A Novel d -Amino Acid-Composed GRPR-Targeted Peptide in Glioma},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c00756}
}
Kostenlos starten →